Brief: Arvinas Inc - 8-K SEC Filing
19/11/2024 11:16
Nov 19 (Reuters) - Arvinas Inc ARVN.O :
* ARVINAS INC - VERITAC-2 TRIAL COMPLETION DATE MOVED TO
JANUARY
2025
* ARVINAS INC: TOP-LINE DATA FROM VERITAC-2 PHASE 3
SECOND-LINE
CLINICAL TRIAL ANTICIPATED IN THE FIRST QUARTER OF 2025
Further company coverage: ARVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology